Mr Pierre Chancel, senior VP, global diabetes, Sanofi
Toujeo is a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes.
Toujeo is expected to be available in the US at the beginning of Q2 2015.
"Sanofi is proud of its long heritage in diabetes and insulin therapies, including Lantus which has supported patients in the management of their diabetes for more than a decade. With the FDA approval of Toujeo, Sanofi builds on its strong legacy and looks forward to bringing a new treatment option to people living with diabetes," said Mr Pierre Chancel, senior VP, global diabetes, Sanofi.